Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten reiterates an Outperform rating on Sutro Biopharma (NASDAQ:STRO) and maintains an $8 price target.

May 14, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst David Nierengarten reaffirmed an Outperform rating on Sutro Biopharma, with a price target of $8, indicating a positive outlook on the stock.
Analyst ratings, especially those with a positive outlook such as an Outperform rating, can influence investor sentiment and potentially lead to an increase in stock price. Maintaining a price target significantly above the current trading price suggests confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100